Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

A new lab study finds that erythritol, a common zero-calorie sweetener, may impair brain blood vessel cell function and affect stroke risk pathways.

By targeting the endothelin pathway, PER-001 introduces a novel, every 6 months therapy, that can address the underlying neurovascular disease and offer vision benefits with the potential to be ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

Erythritol is also synthesized endogenously from glucose and fructose via the pentose phosphate pathway, leaving baseline levels subject ... nitric oxide bioavailability, endothelin production, and ...

The New England Patriots continue to make adjustments to their defensive front.